Drug Trial Radar · NCT06000956
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Sep 11, 2023
Primary completion
Dec 1, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Tasly Pharmaceutical Group Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: * Based on the proportion of participants who achieved improvement in ASAS20, evaluate whether the efficacy of Jitongning tablets is superior to placebo in active ax-SpA adult participants. * Evaluate the efficacy of Jitongning tablets in improving other key functions and symptom outcomes. * Evaluating the safety of Jitongning tablets in adult ax-SpA participants. Participants will 1. take orally Jitongning tablets or a simulated agent of Jitongning tablets. 2. Receive examinations and follow-up visits.
Conditions
- Ankylosing Spondylitis
Interventions
Jitongning tabletsDrug
The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
a simulated agent of Jitongning tabletsDrug
The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ASAS20Time frame: 8 weeks
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Dongfang Hospital, Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China · Recruiting
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Recruiting
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Suzhou Hospital of Traditional Chinese Medicine
Suzhou, Jiangsu, China · Recruiting
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China · Recruiting
The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin, Tianjin Municipality, China · Recruiting
Yunnan Province Hospital of Traditional Chinese Medicine
Kunming, Yunnan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.